open access

Vol 7, No 3 (2014)
Review paper
Published online: 2014-10-23
Get Citation

Immune tolerance induction in patients with haemophilia and inhibitors in the light of new studies

Krystyna Zawilska
Journal of Transfusion Medicine 2014;7(3):97-101.

open access

Vol 7, No 3 (2014)
REVIEWS
Published online: 2014-10-23

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Immune tolerance induction in patients with haemophilia and inhibitors in the light of new studies

Journal

Journal of Transfusion Medicine

Issue

Vol 7, No 3 (2014)

Article type

Review paper

Pages

97-101

Published online

2014-10-23

Bibliographic record

Journal of Transfusion Medicine 2014;7(3):97-101.

Authors

Krystyna Zawilska

References (25)
  1. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992; 339(8793): 594–598.
  2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003; 9(4): 418–435.
  3. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998; 4: 558–563.
  4. Kempton CL, Soucie JM, Miller CH, et al. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost. 2010; 8(10): 2224–2231.
  5. Eckhardt CL, van der Bom JG, van der Naald M, et al. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost. 2011; 9(10): 1948–1958.
  6. Coppola A, Di Minno MND, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol. 2010; 150(5): 515–528.
  7. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2012; 19(1): e1–e47.
  8. Batorova A, Morongova A, Tagariello G, et al. Challenges in the management of hemophilia B with inhibitor. Semin Thromb Hemost. 2013; 39(7): 767–771.
  9. Beutel K, Hauch H, Rischewski J, et al. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie. 2009; 29(2): 155–157.
  10. DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007; 13 Suppl 1: 1–22.
  11. Astermark J, Morado M, Rocino A, et al. EHTSB. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia. 2006; 12(4): 363–371.
  12. Hay CRM, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006; 133(6): 591–605.
  13. Nakar C.T., Manco-Johnson M.J., Lail A. i wsp. Prompt immune tolerance induction at inhibitor diagnosis regardless of titer may increase overall success in hemophilia A with inhibitors: experience of two US centers. 55 th ASH Meeting, 2013; abstr. 575.
  14. Hay CRM, DiMichele DM. International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119(6): 1335–1344.
  15. Athale AH, Marcucci M, Iorio A. Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. Cochrane Database Syst Rev. 2014(4): CD010561.
  16. Kreuz W., Escuriola-Ettingshausen C. Observational Immune Tolerance Induction (ObsITI) research program. www.obsiti.com.
  17. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis. 2005; 16 Suppl 1: S27–S31.
  18. Gensana M, Altisent C, Aznar JA, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia. 2001; 7(4): 369–374.
  19. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica. 2003; 88(6): EREP05.
  20. Orsini F, Rotschild C, Beurrier P, et al. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica. 2005; 90(9): 1288–1290.
  21. Gringeri A, Musso R, Mazzucconi MG, et al. RITS-FITNHES Study Group. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007; 13(4): 373–379.
  22. Greninger DA, Saint-Remy JM, Jacquemin M, et al. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia. 2008; 14(2): 295–302.
  23. Kurth M, Puetz J, Kouides P, et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost. 2011; 9(11): 2229–2234.
  24. Valentino LA, Recht M, Dipaola J, et al. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A. Haemophilia. 2009; 15(3): 718–726.
  25. Van Ve, Peters M, van de, et al. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review. Br J Haematol . : 1–11.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl